BioSpace News Archive

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced the limited commercial launch and completion of initial surgeries of the Mariner® MIS Wayfinder System.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer.

Lantern Pharma, a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform the cost, pace, and timeline of oncology drug discovery and development, provided a business update and reported financial results for the third quarter ended September 30, 2021.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry.

Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced that the Company will host a conference call and live audio webcast on Monday, November 8, 2021 at 4:30 p.m. ET to report third quarter 2021 financial results and provide a corporate update.

Compass Therapeutics, Inc., a clinical stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced that it intends to offer and sell shares of common stock in an underwritten public offering.

Fabrinet, a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, announced its financial results for its first fiscal quarter ended September 24, 2021.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 13,000 shares of G1’s common stock to one employee under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, and an aggregate of 48,600 shares of G1’s common stock to one employee under the previously-announced G1 Therapeutics, Inc.

GC Pharma announced that the European Medicines Agency granted orphan drug designation to Hunterase ICV ) for the treatment of mucopolysaccharidosis type II in the European Union.

Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced that it has priced an underwritten public offering to sell 35,715,000 shares of common stock at a public offering price of $3.50 per share.